Literature DB >> 2332239

Control of regional blood flow by endothelium-derived nitric oxide.

S M Gardiner1, A M Compton, T Bennett, R M Palmer, S Moncada.   

Abstract

The regional hemodynamic consequences of inhibiting vascular endothelial nitric oxide generation with NG-monomethyl-L-arginine (L-NMMA) were studied in conscious Long-Evans rats. Experiments were carried out in groups of chronically instrumented rats with intravascular catheters and pulsed Doppler probes to monitor regional blood flow. L-NMMA (0.3-300 mg/kg) caused a dose-dependent, long-lasting (5-90 minutes), and enantiomerically specific increase in mean blood pressure and also caused bradycardia. The increase in blood pressure was accompanied by a dose-dependent and long-lasting vasoconstriction in the internal carotid, mesenteric, renal, and hindquarters vascular beds that could be attenuated, in a concentration-dependent manner, by L-arginine but not by D-arginine. In contrast, L-arginine did not affect the pressor or vasoconstrictor effects of vasopressin. These results indicate that nitric oxide production by vascular endothelial cells contributes to the maintenance of blood pressure and to the control of the resting tone of different vascular beds in the conscious rat.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332239     DOI: 10.1161/01.hyp.15.5.486

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  88 in total

1.  Tonic inhibitory control exerted by opioid peptides in the paraventricular nuclei of the hypothalamus on regional hemodynamic activity in rats.

Authors:  Andrée Lessard; Hélène Bachelard
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

2.  Involvement of capsaicin-sensitive neurones in the haemodynamic effects of exogenous vasoactive peptides: studies in conscious, adult Long Evans rats treated neonatally with capsaicin.

Authors:  H Bachelard; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  Coronary vasoconstriction in the conscious rabbit following intravenous infusion of L-NG-nitro-arginine.

Authors:  R G Humphries; R D Carr; A K Nicol; W Tomlinson; S E O'Connor
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

4.  2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo.

Authors:  W S Faraci; A A Nagel; K A Verdries; L A Vincent; H Xu; L E Nichols; J M Labasi; E D Salter; E R Pettipher
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

5.  Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat.

Authors:  J G Filep; E Földes-Filep; A Rousseau; P Sirois; A Fournier
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock.

Authors:  C Szabó; J A Mitchell; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

7.  Regulation of baseline vascular resistance in the canine diaphragm by nitric oxide.

Authors:  M E Ward; S N Hussain
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Inhibition of endogenous nitric oxide reduces basal mesenteric vascular tone but does not alter intraduodenal hydrochloric acid-induced intestinal hyperemia in rats.

Authors:  J Kao; F Iwata; X Y Zhang; M Baker; K Seno; F W Leung
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  The ocular hemodynamic response to nitric oxide synthase inhibition is unaltered in patients with early type I diabetes.

Authors:  Guido T Dorner; Gerhard Garhöfer; Nicole Selenko; Peter Fasching; Michaela Bayerle-Eder; Leopold Schmetterer; Michael Wolzt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-26       Impact factor: 3.117

10.  Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.

Authors:  A A Quyyumi; N Dakak; N P Andrews; S Husain; S Arora; D M Gilligan; J A Panza; R O Cannon
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.